Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Organisation › Details

BeiGene (Group)

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents. *


Period Start 2013-05-31 existent
Products Industry B-Raf kinase inhibitor
  Industry 2 cancer drug
Person Person Oyler, John V. (BeiGene 201305 CEO + Co-Founder)
Region Region Beijing (Peking)
  Country China
  Street 30 Science Park Road
Zhongguancun Life Science Park, Changping District
  City 102206 Beijing
  Tel +86-010-851 48500
    Address record changed: 2024-01-05
Basic data Employees G: 5,001 to 10,000 (2021-11-23)
  Currency USD
  Annual sales 308,874,000 (revenues, total, consolidated (2020) 2020-12-31)
  Profit -1,600,523,000 (2020-12-31)
  Cash 1,381,950,000 (2020-12-31)
    * Document for »About Section«: BeiGene, Ltd.. (11/23/21). "Press Release: BeiGene Launches Proposed Initial Public Offering on the STAR Market in China". Cambridge, MA & Beijing.
Record changed: 2023-07-10


Picture [iito] [LSE] Business Portal 650x200px

More documents for BeiGene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top